2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4242 Impact of HLA-DPB1 matching and permissiveness on graft-versus-host disease, relapse, and survival in 10/10 HLA-identical allogeneic hematopoietic cell transplantation with universal anti-thymocyte globulin prophylaxis

Daiana Gisela Rodriguez, MD, Omar Eduardo Fernandez Vargas, MD, MSc2, Imran Ahmad, MD, MSc3, Lea Bernard, MD4, Sandra Cohen, MD5, Jean-Sebastien Delisle, MD, PhD6, Thomas Kiss, MD7, Denis-Claude Roy, MD8, Jean Roy, MD9, Guy Sauvageau, MD,PhD10, Sylvie Lachance, MD, FRCPC, DRCPC11
1 Université de Montréal, Montreal, Quebec, Canada
2 Université de Montreal, Montreal, Quebec, Canada
3 Université de Montreal, Montreal, Quebec, Canada
4 Université de Montreal, Montreal, Quebec, Canada
5 Université de Montreal, Montreal, Quebec, Canada
6 Université de Montreal, Montreal, Quebec, Canada
7 Université de Montreal, Montreal, Quebec, Canada
8 Université de Montreal, Montreal, Quebec, Canada
9 Université de Montreal, Montreal, Quebec, Canada
10 Université de Montreal, Montreal, Quebec, Canada
11 Université de Montréal, Montreal, Canada

Background

In 10/10 HLA-matched allogeneic hematopoietic cell transplantation (HCT), non-permissive HLA-DPB1 mismatches (DPB1-mm) have been associated with an increased risk of graft-versus-host disease (GVHD), whereas permissive mismatches may improve survival potentially through enhanced graft-versus-leukemia (GVL) activity. Although anti-thymocyte globulin (ATG)-based GVHD prophylaxis (px), effectively attenuates HLA DPB1-driven alloreactivity via in vivo T-cell depletion, its impact on the GVL activity remains unknown

Aims
To evaluate the impact of HLA-DPB1 disparities on transplantation outcomes following 10/10 HLA-matched related donor (MRD) or matched unrelated donor (MUD) HCT using universal ATG-based GVHD prophylaxis.

Methods
This retrospective single-center study included 214 consecutive patients undergoing first 10/10 HLA-matched HCT between January 2020 and May 2025 at Maisonneuve-Rosemont Hospital, Montreal, Canada. Among them, 69 patients were HLA-DPB1 matched (DPB1-m), including 44 siblings and 145 were DPB1-mm. Of the latter, 29 (20%) were non-permissive mismatches (DPB1-np). All patients received
rabbit ATG-based GVHD px administered at a median dose of 2.5 mg/kg on days  -3 and -2, combined with a calcineurin inhibitor initiated on day -1 and either methotrexate or mycophenolate mofetil.  Remission status at HCT was classified  as in remission or not in remission. Overall survival (OS), disease-free survival (DFS) and GVHD-free, relapse-free survival (GRFS), were estimated using Kaplan-Meier method. Multivariable cox and Fine-Gray or regression analysis were performed to identify predictors of outcomes.

Results

Among 214 patients included: 69 (32%) were DPB1-m, 116 (54%) DPB1-mm permissive (DPB1-p), and 29 (14%) DPB1-np. Median recipient age was 53.2 years, with a median follow-up of 38.3 months. Baseline characteristics were generally balanced between groups. Acute leukemia (AML 40%, ALL 18%) was the leading indication for HCT in both groups. High DRI accounted for 14.5% and 11% of DPB1-m and DPB1-mm pts (p=0.47).  Non-Caucasian ethnicity was more prevalent among DPB1-mm recipients (20% versus 6% (p=0.002).  More DPB1-mm patients underwent transplantation with active disease (22% (n=32) vs 10% (n=10) for DPB1-m; p=0.04). Conditioning intensity and total body irradiation exposure were similar between groups. MUD transplants represented the majority of the DPB1-mm cohort and donors were significantly younger (25-y) than matched related donors (40-y) (p<0.001).

The estimated 36-month DFS was 71.5%. Relapse incidence was comparable between DPB1-m and DPB1-mm recipients at  2 years (24%). Despite a higher rate of active disease at transplantation, DPB1-mm recipients achieved DFS comparable to that of DPB1-m patients (71,3% vs. 72%:p=0.4). As expected, multivariable analysis showed a trend toward higher relapse risk for pts not in remission (aHR=1.9, p=0.06). and a non-significant lower relapse risk in DPB1-mm (aHR=0.7, p=0.19). Non-relapse mortality plateaued at 4.6% after month 12 and remained nearly identical across cohorts. The cumulative incidence of acute GVHD was 29.4% at day 100 and 33.2% at day 180 not significantly different between DPB1-m and DPB1-mm recipients (22% vs. 33% p=0.18, and 25% vs. 37%, p=0.14), as well as between permissive and non-permissive mismatch groups. Non-permissive DPB1-mm in the GVH vector showed a trend toward higher early acute GVHD (HR p=0.058). Grade III-IV acute GVHD occurred in 11% of patients and was not significantly influenced by DPB1 matching status (p=0.28), or mismatch permissiveness (p=0.6).

Chronic GVHD incidence remained similar between groups being 10.4% at 6 mo (11% DPB1-mm vs. 8.8% DPB1-m; p=0.6) and 23.4% at 12 mo (24.2% DPB1-mm vs. 21.8% in DPB1-m; p=0.54).  Severe chronic GVHD occurred in only 6,9%. GVHD-free, relapse-free survival (GRFS) reached 50.8% at 24 months (46.3% for DPB1-mm vs 53% for DPB1-m; p=0.4). Active disease at transplantation was the only independent predictor of GRFS failure (p=0.006).

Conclusion
In 10/10 HLA-matched allogeneic HCT, universal ATG-based GVHD prophylaxis appears to minimize the adverse immunologic effects traditionally associated with HLA-DPB1 disparities on GVHD incidence and severity while preserving the graft-versus-leukemia effect. These findings translated into excellent 3-year DFS, low non-relapse mortality and favorable GVHD-free, relapse-free survival irrespective of HLA-DPB1 matching status suggesting 

 


Daiana Gisela Rodriguez, MD: No relevant conflicts of interest to declare.